Trends in Immunology
ReviewHIV Latency: Should We Shock or Lock?
Section snippets
HIV-1 As a Chronic Infection
The advent of improved cART allows clinicians to successfully manage HIV-infected patients and to decrease side effects. However, cART is not curative, and a new set of HIV-associated complications have emerged, resulting in a chronic disease that for many will span several decades of life.
Furthermore, cART interruption leads to the re-emergence of a detectable level of viremia because HIV-1 persists in viral reservoirs [1]. These reservoirs, defined as a cell type or anatomical site where the
Regulation of HIV-1 Transcription
Latently infected cells maintain a suboptimal cellular environment for HIV-1 expression via several mechanisms operating at the post-transcriptional level 13, 14 but predominantly at the transcriptional level.
The processes which cause the transcriptional inhibition are of interest given their potential to be manipulated to activate HIV-1 expression and hopefully allow latently infected cells to be eliminated, or, by contrast, to permanently silence HIV-1 transcription. HIV-1 latency results
The Shock and Kill Strategy
Recent cases (e.g., Timothy Brown [25], the Boston patients [26], the Mississippi child [27], the VISCONTI cohort [28], and the perinatally infected child who received treatment early [29]) have fueled hopes for HIV-1 cure or durable control. However, treatment interruption trials have revealed a correlation between total HIV-1 DNA levels and time to viral rebound following cART interruption 30, 31. At least partially, the HIV-1 reservoir size predicts the timing of viral rebound after cART
Concluding Remarks and Future Directions
Intensive efforts have been made by the scientific community to characterize HIV-1 latent reservoirs and to investigate the molecular mechanisms regulating HIV-1 latency. Improved knowledge of the mechanisms of persistence has paved the way for innovative strategies to decrease/eliminate latent HIV. One strategy for HIV-1 eradication consists of combinations of LRAs acting on several silencing molecular mechanisms to force viral expression at different levels. Coupled to immune interventions,
Acknowledgments
We acknowledge grant support from the ANRS (France Recherche Nord&Sud Sida - HIV Hépatites), the Belgian Fund for Scientific Research (FRS-FNRS), the Fondation Roi Baudouin, the NEAT program (Networking to Enhance the Use of Economics in Animal Health Education, Research, and Policy Making), the Walloon Region (Fonds de Maturation) and the University of Brussels [Action de Recherche Concertée (ARC) grant].
G.D. and C.V.L. are “Aspirant” and “Directeur de Recherches” of the FRS-FNRS (Belgium),
Glossary
- Enhancer trapping
- this phenomenon occurs when the enhancer located in the HIV-1 5’- long terminal repeat (LTR) is hijacked by a nearby promoter of a cellular gene and acts on the transcriptional activity of this cellular promoter, thereby preventing enhancer action on the viral promoter.
- Ex vivo HIV-1 latency studies
- assays performed using cultures of cells (mainly CD8+-depleted peripheral blood mononuclear cells or resting CD4+ T cells) isolated from the blood of HIV+ cART-treated individuals.
- In
References (100)
NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II
Mol. Cell
(2001)HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report
Lancet HIV
(2016)Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription
J. Biol. Chem.
(2013)Reactivation of latent HIV-1 by new semi-synthetic ingenol esters
Virology
(2014)Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294
J. Biol. Chem.
(2010)The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response
FEBS Lett.
(2011)Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells
J. Biol. Chem.
(2015)Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein
J. Biol. Chem.
(2012)Reactivation of latent HIV-1 by inhibition of BRD4
Cell Rep.
(2012)Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Lancet HIV
(2015)